Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Zepbound is also used to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. An interaction can occur because one substance causes another substance to have a different ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

And Zepbound is approved to reduce the risk of obstructive sleep apnea in people with obesity. The current findings should help doctors better understand which drug might be right for which patient.

Sleep apnea could be costing you brain power and increasing your risk of dementia and Alzheimer's disease, a new study says.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

while Zepbound is approved for weight loss in adults with a BMI of 30 or higher if they have a related condition like high blood pressure, high cholesterol, Type 2 diabetes, sleep apnea or heart ...